Why is the ResMed share price taking a thumping on Thursday?

Investors seem to be signalling out ResMed for punishment.

| More on:
Shot of a scientist using a computer while conducting research in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a fairly miserable Thursday session for ASX shares so far today. At the time of writing, the S&P/ASX 200 Index (ASX: XJO) has slipped by 0.04% and is back under 8,140 points. But let's talk about what's going on with the ResMed CDI (ASX: RMD) share price.

Whilst the ASX 200 is having a bad day, it's been far worse for Resmed shares. This ASX 200 healthcare stock closed at $36.25 a share yesterday. But this morning, those same shares opened at just $35.30 and are now down a painful 3.5% at $34.98 each.

So why is the Resmed share price getting such a dramatic hammering this session?

What's up with the ResMed share price today?

Well, it's hard to know for sure. There haven't been any fresh developments or news out of Resmed itself today on the ASX.

But there are still a few things we can point out.

Firstly, it's been a pretty rough day for most ASX healthcare stocks. The healthcare sector is currently the third-worst performing sector on the markets, with the S&P/ASX 200 Health Care Index (ASX: XHJ) currently down 0.65%.

Other healthcare shares, such as CSL Ltd (ASX: CSL), Polynovo Ltd (ASX: PNV), and Cochlear Ltd (ASX: COH), are also suffering today.

Secondly, Resmed's US-listed stock ResMed Inc (NYSE: RMD) also had a pretty bad night last night. Resmed has a dual-listed structure, meaning its shares can be found both on the Australian market and on the New York Stock Exchange. The American shares often set the tone for what happens on the ASX.

Last night, Resmed's American share price had a shocker, falling 5.12% to US$238.03 a share.

Our Fool colleagues over in the States posited that this fall might be a result of a broker downgrade. Wolfe Research's Mike Polark reportedly moved Resmed shares from a hold to a sell.

Resmed gets a sell rating

He also gave the company a 12-month share price target of US$180 per share, which, if accurate, would see the company lose a quarter of its value from current levels.

Polark's pessimism stems from concerns that Resmed might be poised to lose market share to its pharmaceutical rival Eli Lilly. He argued that "disruption risks to RMD's business rise in 2025-2026 due to Lilly's likely launch of an obstructive sleep apnea indication for its GLP-1 medication tirzepatide".

So that might have been what tanked Resmed's US stock last night, and thus indirectly responsible for today's poor ASX showing from the Resmed share price.

Despite today's sell-off, Resmed's ASX shares remain up a robust 37.7% in 2024 and 53.9% over the past 12 months.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, PolyNovo, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL, Cochlear, and PolyNovo. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »